1478-6354 < 1478-6362 < 1478-811X

Facettes : Author.f AffPays.f AffRegion.f AffVille.f AffOrg.f KwdFr.f Mesh.f MeshFr.f Teeft.f

List of bibliographic references indexed by 1478-6362

Number of relevant bibliographic references: 118.
[0-20] [0 - 20][0 - 50][20-40]

Ident.	Authors (with country if any)	Title
000030 (2020)	Gulzhan Trimova ; Kaoru Yamagata ; Shigeru Iwata ; Shintaro Hirata [Japon] ; Tong Zhang ; Fumi Uemura ; Minoru Satoh [Japon] ; Norma Biln ; Shingo Nakayamada ; Walter P. Maksymowych ; Yoshiya Tanaka	Tumour necrosis factor alpha promotes secretion of 14-3-3η by inducing necroptosis in macrophages
000040 (2020)	S. Panopoulos [Grèce] ; Chatzidionysiou [Grèce] ; M. G. Tektonidou [Grèce] ; V. K. Bournia [Grèce] ; A. A. Drosos [Grèce] ; Stamatis-Nick C. Liossis [Grèce] ; T. Dimitroulas [Grèce] ; L. Sakkas [Grèce] ; D. Boumpas [Grèce] ; P. V. Voulgari [Grèce] ; D. Daoussis [Grèce] ; K. Thomas [Grèce] ; G. Georgiopoulos [Grèce] ; G. Vosvotekas [Grèce] ; Garyfallos [Grèce] ; P. Sidiropoulos [Grèce] ; G. Bertsias [Grèce] ; D. Vassilopoulos [Grèce] ; P. P. Sfikakis [Grèce]	Treatment modalities and drug survival in a systemic sclerosis real-life patient cohort
000159 (2020)	Cem Gabay [Suisse] ; Gerd R. Burmester [Allemagne] ; Vibeke Strand [États-Unis] ; Jérôme Msihid [France] ; Moshe Zilberstein [États-Unis] ; Toshio Kimura [États-Unis] ; Hubert Van Hoogstraten [États-Unis] ; Susan H. Boklage [États-Unis] ; Jonathan Sadeh [États-Unis] ; Neil M. H. Graham [États-Unis] ; Anita Boyapati [États-Unis]	Sarilumab and adalimumab differential effects on bone remodelling and cardiovascular risk biomarkers, and predictions of treatment outcomes
000168 (2020)	Tsutomu Takeuchi [Japon] ; Yoshiya Tanaka [Japon] ; Sakae Tanaka [Japon] ; Atsushi Kawakami [Japon] ; Yeong-Wook Song [Corée du Sud] ; Yi-Hsing Chen [Taïwan] ; Mitsuhiro Rokuda [Japon] ; Hiroyuki Izutsu [Japon] ; Satoshi Ushijima [Japon] ; Yuichiro Kaneko [Japon] ; Yoshihiro Nakashima [Japon] ; Teruaki Shiomi [Japon] ; Emi Yamada [Japon]	Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan
000247 (2020)	Gabriella Giancane [Italie] ; Joost F. Swart [Pays-Bas] ; Elio Castagnola [Italie] ; Andreas H. Groll [Allemagne] ; Gerd Horneff [Allemagne] ; Hans-Iko Huppertz [Allemagne] ; Daniel J. Lovell [États-Unis] ; Tom Wolfs [Pays-Bas] ; Troels Herlin [Danemark] ; Pavla Dolezalova [République tchèque] ; Helga Sanner [Norvège] ; Gordana Susic [Serbie] ; Flavio Sztajnbok [Brésil] ; Despoina Maritsi [Grèce] ; Tamas Constantin [Hongrie] ; Veronika Vargova [Slovaquie] ; Sujata Sawhney [Inde] ; Marite Rygg [Norvège] ; Sheila K. Oliveira [Brésil] ; Marco Cattalini [Italie] ; Francesca Bovis [Italie] ; Francesca Bagnasco [Italie] ; Angela Pistorio [Italie] ; Alberto Martini [Italie] ; Nico Wulffraat [Pays-Bas] ; Nicolino Ruperto [Italie]	Opportunistic infections in immunosuppressed patients with juvenile idiopathic arthritis: analysis by the Pharmachild Safety Adjudication Committee
000324 (2020)	Sae Ochi [Japon] ; Kazuyoshi Saito [Japon] ; Fumitaka Mizoguchi [Japon] ; Shigeaki Kato [Japon] ; Yoshiya Tanaka [Japon]	Insensitivity versus poor response to tumour necrosis factor inhibitors in rheumatoid arthritis: a retrospective cohort study
000327 (2020)	Jakob Einhaus [Allemagne] ; Ann-Christin Pecher [Allemagne] ; Elisa Asteriti [Allemagne] ; Hannes Schmid [Allemagne] ; Kathy-Ann Secker [Allemagne] ; Silke Duerr-Stoerzer [Allemagne] ; Hildegard Keppeler [Allemagne] ; Reinhild Klein [Allemagne] ; Corina Schneidawind [Allemagne] ; Joerg Henes [Allemagne] ; Dominik Schneidawind [Allemagne]	Inhibition of effector B cells by ibrutinib in systemic sclerosis
000572 (2020)	Takahiko Sugihara [Japon] ; Hitoshi Hasegawa ; Haruhito A. Uchida [Japon] ; Hajime Yoshifuji [Japon] ; Yoshiko Watanabe [Japon] ; Eisuke Amiya [Japon] ; Yasuhiro Maejima [Japon] ; Masanori Konishi [Japon] ; Yohko Murakawa [Japon] ; Noriyoshi Ogawa [Japon] ; Shunsuke Furuta [Japon] ; Yasuhiro Katsumata [Japon] ; Yoshinori Komagata [Japon] ; Taio Naniwa [Japon] ; Takahiro Okazaki [Japon] ; Yoshiya Tanaka [Japon] ; Tsutomu Takeuchi [Japon] ; Yoshikazu Nakaoka [Japon] ; Yoshihiro Arimura [Japon] ; Masayoshi Harigai [Japon] ; Mitsuaki Isobe [Japon]	Associated factors of poor treatment outcomes in patients with giant cell arteritis: clinical implication of large vessel lesions
000599 (2020)	Giovanni Cagnotto [Suède] ; Minna Willim [Suède] ; Jan- Ke Nilsson [Suède] ; Michele Compagno [Suède] ; Lennart T. H. Jacobsson [Suède] ; Saedis Saevarsdottir [Suède] ; Carl Turesson [Suède]	Abatacept in rheumatoid arthritis: survival on drug, clinical outcomes, and their predictors—data from a large national quality register
000795 (2019)	Daniel E. Furst ; James S. Louie	Targeting inflammatory pathways in axial spondyloarthritis
000839 (2019)	Kazuki M. Matsuda [Japon] ; Ayumi Yoshizaki [Japon] ; Ai Kuzumi [Japon] ; Takemichi Fukasawa [Japon] ; Satoshi Ebata [Japon] ; Shunsuke Miura [Japon] ; Tetsuo Toyama [Japon] ; Asako Yoshizaki [Japon] ; Hayakazu Sumida [Japon] ; Yoshihide Asano [Japon] ; Koji Oba [Japon] ; Shinichi Sato [Japon]	Skin thickness score as a surrogate marker of organ involvements in systemic sclerosis: a retrospective observational study
000844 (2019)	Kotaro Matsumoto [Japon] ; Katsuya Suzuki [Japon] ; Keiko Yoshimoto [Japon] ; Noriyasu Seki ; Hideto Tsujimoto ; Kenji Chiba ; Tsutomu Takeuchi [Japon]	Significant association between clinical characteristics and changes in peripheral immuno-phenotype in large vessel vasculitis
000866 (2019)	Gulsen Ozen [États-Unis] ; Sofia Pedro [États-Unis] ; Rebecca Schumacher [États-Unis] ; Teresa A. Simon [États-Unis] ; Kaleb Michaud [États-Unis]	Safety of abatacept compared with other biologic and conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: data from an observational study
000879 (2019)	Wataru Fukuda ; Tadamasa Hanyu ; Masaki Katayama ; Shinichi Mizuki ; Akitomo Okada ; Masayuki Miyata ; Yuichi Handa ; Masatoshi Hayashi ; Yoshinobu Koyama ; Kaoru Arii ; Toshiyuki Kitaori ; Hiroyuki Hagiyama ; Yoshinori Urushidani ; Takahito Yamasaki ; Yoshihiko Ikeno ; Takeshi Suzuki ; Atsushi Omoto ; Toshifumi Sugitani ; Satoshi Morita ; Shigeko Inokuma	Risk stratification and clinical course of hepatitis B virus reactivation in rheumatoid arthritis patients with resolved infection: final report of a multicenter prospective observational study at Japanese Red Cross Hospital
000987 (2019)	Denis Choquette [Canada] ; Louis Bessette [Canada] ; Evo Alemao [États-Unis] ; Boulos Haraoui [Canada] ; Roelien Postema [Royaume-Uni] ; Jean-Pierre Raynauld [Canada] ; Louis Coupal [Canada]	Persistence rates of abatacept and TNF inhibitors used as first or second biologic DMARDs in the treatment of rheumatoid arthritis: 9 years of experience from the Rhumadata® clinical database and registry
000A65 (2019)	Victor Farutin [États-Unis] ; Thomas Prod Omme [États-Unis] ; Kevin Mcconnell [États-Unis] ; Nathaniel Washburn [États-Unis] ; Patrick Halvey [États-Unis] ; Carol J. Etzel [États-Unis] ; Jamey Guess [États-Unis] ; Jay Duffner [États-Unis] ; Kristen Getchell [États-Unis] ; Robin Meccariello [États-Unis] ; Bryan Gutierrez [États-Unis] ; Christopher Honan [États-Unis] ; Ganlin Zhao [États-Unis] ; Nicholas A. Cilfone [États-Unis] ; Nur Sibel Gunay [États-Unis] ; Jan L. Hillson [États-Unis] ; David S. Deluca [Allemagne] ; Katherine C. Saunders [États-Unis] ; Dimitrios A. Pappas [États-Unis] ; Jeffrey D. Greenberg [États-Unis] ; Joel M. Kremer [États-Unis] ; Anthony M. Manning [États-Unis] ; Leona E. Ling [États-Unis] ; Ishan Capila [États-Unis]	Molecular profiling of rheumatoid arthritis patients reveals an association between innate and adaptive cell populations and response to anti-tumor necrosis factor
000A91 (2019)	Serena Colafrancesco [Italie] ; Maria Manara [Italie] ; Alessandra Bortoluzzi ; Teodora Serban [Italie] ; Gerolamo Bianchi [Italie] ; Luca Cantarini [Italie] ; Francesco Ciccia [Italie] ; Lorenzo Dagna [Italie] ; Marcello Govoni ; Carlomaurizio Montecucco [Italie] ; Roberta Priori [Italie] ; Angelo Ravelli [Italie] ; Paolo Sfriso [Italie] ; Luigi Sinigaglia [Italie]	Management of adult-onset Still’s disease with interleukin-1 inhibitors: evidence- and consensus-based statements by a panel of Italian experts
000B70 (2019)	Aleksey Mitev [Allemagne] ; Lisa Christ [Suisse] ; Daria Feldmann [Allemagne] ; Moritz Binder [États-Unis] ; Kim Möller [Royaume-Uni] ; Anna-Maria Kanne [Allemagne] ; Thomas Hügle [Suisse] ; Peter M. Villiger [Suisse] ; Reinhard E. Voll [Allemagne] ; Stephanie Finzel [Allemagne] ; Florian Kollert [Suisse]	Inflammatory stays inflammatory: a subgroup of systemic sclerosis characterized by high morbidity and inflammatory resistance to cyclophosphamide
000C44 (2019)	Vibeke Strand [États-Unis] ; Sophie Dimonaco [Royaume-Uni] ; Katie Tuckwell [États-Unis] ; Micki Klearman [États-Unis] ; Neil Collinson [Royaume-Uni] ; John H. Stone [États-Unis]	Health-related quality of life in patients with giant cell arteritis treated with tocilizumab in a phase 3 randomised controlled trial.
000C46 (2019)	Naomi Tsuchida [Japon] ; Yohei Kirino [Japon] ; Yutaro Soejima [Japon] ; Masafumi Onodera [Japon] ; Katsuhiro Arai [Japon] ; Eiichiro Tamura [Japon] ; Takashi Ishikawa [Japon] ; Toshinao Kawai [Japon] ; Toru Uchiyama [Japon] ; Shigeru Nomura [Japon] ; Daisuke Kobayashi [Japon] ; Masataka Taguri [Japon] ; Satomi Mitsuhashi [Japon] ; Takeshi Mizuguchi [Japon] ; Atsushi Takata [Japon] ; Noriko Miyake [Japon] ; Hideaki Nakajima [Japon] ; Satoko Miyatake [Japon] ; Naomichi Matsumoto [Japon]	Haploinsufficiency of A20 caused by a novel nonsense variant or entire deletion of TNFAIP3 is clinically distinct from Behçet’s disease
000C76 (2019)	Waleed Hafiz [Canada] ; Rawad Nori [Canada] ; Ariana Bregasi ; Babak Noamani ; Dennisse Bonilla ; Larissa Lisnevskaia [Canada] ; Earl Silverman [Canada] ; Arthur A. M. Bookman [Canada] ; Sindhu R. Johnson [Canada] ; Carolina Landolt-Marticorena ; Joan Wither [Canada]	Fatigue severity in anti-nuclear antibody-positive individuals does not correlate with pro-inflammatory cytokine levels or predict imminent progression to symptomatic disease

---

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/Main/Exploration

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/ISSN.i -k "1478-6362" 

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/ISSN.i  \
                -Sk "1478-6362" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    Main
   |étape=   Exploration
   |type=    indexItem
   |index=    ISSN.i
   |clé=    1478-6362
}}

---

This area was generated with Dilib version V0.6.34. Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021